Labcorp advances with new ColoSense launch, shares react after recent underperformance

Labcorp’s ColoSense RNA at-home colorectal cancer test gains nationwide availability and Medicare coverage, while the LH shares stabilize after a weak spell compared to U.S. healthcare peers.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-24, 11:07.

Labcorp (US50540R4092) is pushing deeper into at-home diagnostics with its ColoSense colorectal cancer screening test, as highlighted by recent U.S. coverage. The LH shares trade on the NYSE and have just broken a five-day losing streak, according to MarketWatch.

ColoSense rollout and coverage

PR Newswire reported that Labcorp announced the nationwide availability of ColoSense, described as the first FDA-approved RNA-based at-home colorectal cancer screening test in the United States, on June 22, 2026.IR release via PR Newswire The test is positioned to complement colonoscopy and other non-invasive screening options by targeting early-stage disease.

Simply Wall St notes that ColoSense is now covered for eligible Medicare and Medicare Advantage patients under the updated CMS National Coverage Determination, removing a key reimbursement hurdle for broad adoption in the U.S. screening market.Simply Wall St analysis on Labcorp This coverage is important because colorectal cancer screening recommendations apply to tens of millions of Americans in typical risk cohorts.

Operational push into at-home testing

Medical Device Network summarizes that Labcorp’s ColoSense launch broadens its at-home screening portfolio and is part of a strategy to reduce barriers to preventive care by offering guideline-supported, non-invasive testing outside traditional clinical settings.Medical Device Network coverage The company already offers multiple home sample collection kits, and ColoSense adds an RNA-based modality to that mix.

Simply Wall St also points to the MyLabcorp AI-powered app as another recent initiative designed to deepen Labcorp’s direct connection with patients and physicians, pairing digital tools with physical testing services in a more integrated offering.Simply Wall St commentary on MyLabcorp app Taken together, these projects show a clear operational emphasis on consumer-facing diagnostics rather than purely central-lab workflows.

The product behind the stock

ColoSense is a home-based colorectal cancer screening test that uses RNA biomarkers in stool samples to detect early-stage disease, with FDA approval and CMS coverage for eligible Medicare and Medicare Advantage beneficiaries in the U.S.Labcorp product announcement It fits into Labcorp’s broader diagnostics portfolio, which spans central laboratories and direct-to-consumer testing.

Where the stock trades today

The Labcorp shares (US50540R4092) last closed on the NYSE at 258.59 US dollars on 2026-06-23, based on MarketWatch data.MarketWatch daily stock report This price move represented a 1.64 percent gain that ended a sequence of five consecutive daily declines.

Labcorp key share data

• Company: Laboratory Corporation of America Holdings
• ISIN: US50540R4092
• WKN: 895227
• Ticker: LH
• Trading venue: NYSE
• Price (as of 2026-06-23, 21:30): 258.59 USD
• Market cap: approximately 21.8 billion USD (as of 2026-06-23)
• Sector / industry: Healthcare, Diagnostics Laboratories
• Index membership: S&P 500
• Next earnings date: 2026-07-25 (company schedule, if unchanged)

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Data and sources are believed to be reliable but cannot be guaranteed; investors should conduct their own research or consult a professional advisor before making investment decisions.